Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2020-06-03 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Appendix 3G 14 pages 216.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an ASX announcement titled 'Appendix 3G – Notification of issue, conversion or payment up of equity securities' from PYC Therapeutics Limited dated 4 June 2020. It details the issuance of securities resulting from the exercise of options, including the number of securities issued, dates, and other related information. The document is a regulatory announcement about equity securities issuance and not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues or capital structure changes. The document length is about 15,000 characters, indicating it is a full announcement rather than a brief note or a report publication announcement. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2020-06-03 English
World Class Results - Lions Eye Institute News Release 2 pages 131.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 25 May 2020 from PYC Therapeutics. It primarily communicates a news release from the Lions Eye Institute about progress on a drug for Retinitis Pigmentosa. The text includes a summary of the research and a link to the full news release on the company's website. There are no financial statements, regulatory certifications, or detailed financial data presented. The document is relatively short (3843 characters) and serves as a news update rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of a news release about research progress, which aligns best with a general Regulatory Filing (RNS) as a miscellaneous announcement that does not fit other specific categories.
2020-05-24 English
March 2020 Quarterly Activities and Cash Flow Report 8 pages 150.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activity Report' and includes detailed financial data such as cash flow statements for the quarter ended 31 March 2020. It contains substantive financial information including operating cash flows, investing and financing activities, and cash balances. The presence of detailed financial statements and analysis for a period shorter than a full fiscal year indicates this is a quarterly report. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-04-28 English
Efficacy and Toxicity Studies Presentation 18 pages 2.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation containing scientific data, efficacy and toxicity results, market analysis, and financial case related to a drug development program by PYC Therapeutics. It references previous ASX announcements but primarily focuses on presenting detailed information about the drug's development, scientific validation, and market potential. The document is about 11,560 characters long, which is substantial and contains detailed content rather than just an announcement or a brief summary. It is not a regulatory filing, certification, or a brief announcement of a report. The content aligns with an Investor Presentation (IP) as it provides detailed information for investors about the company's drug development progress, scientific validation, market opportunity, and financial outlook. Therefore, the most appropriate classification is Investor Presentation (IP).
2020-04-14 English
Successful Toxicity Results Confirm Safety Advantage 5 pages 247.9KB
Regulatory Filings Classification · 90% confidence The document is an announcement dated 8 April 2020 from PYC Therapeutics regarding successful toxicity results confirming the safety advantage of their lead drug delivery technology. It discusses pre-clinical efficacy and toxicity validation, safety data from mouse models, and the impact on their drug development pipeline. The content is focused on scientific and clinical progress updates rather than financial results or regulatory filings. There is no indication that this is a full financial report, audit report, or regulatory filing. It is a corporate announcement about research and development progress, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a presentation or transcript, nor does it relate to governance, management changes, or capital structure. The document is a detailed announcement of scientific results and program progress, which aligns best with a Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2020-04-07 English
Successful Efficacy Result on Path to First in Human Studies 10 pages 580.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 1 April 2020 from PYC Therapeutics. It discusses successful efficacy results of their lead drug in preclinical disease models and outlines plans for First In Human studies scheduled for 2021. The content focuses on scientific results, drug development progress, market potential, and next steps in clinical development. There are no financial statements, quarterly or annual results, or detailed management discussion of financial performance. The document is not a transcript of a call, nor is it a regulatory filing or certification. It is a corporate announcement about drug development progress and upcoming clinical trials, which fits best under Capital/Financing Update (CAP) as it relates to progress in drug development and funding status to advance the program. The document is substantive and not a brief report publication announcement or a simple regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2020-03-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.